| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Drugs Made In America Acquisition II Corp.
13D
DMII · G2851K104
|
10.2% |
10/2/2025
Event 10/1/2025
|
||||
| Drugs Made In America Acquisition II LLC | 10.2% | |||||
| Lynn Stockwell | 10.2% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.